MS8709 (compound 10), a potential anticancer therapeutic, is a first-in-class G9a/GLP PROTAC degrader. MS8709 is based on G9a/GLP inhibitor UNC0642 and recruits the von Hippel Lindau (VHL) E3 ligase (Red: G9a/GLP inhibitor UNC0642; Blue: VHL ligand; Black: linker)[1].
References
[1] Julia Velez, et al. Discovery of the First-in-class G9a/GLP PROTAC Degrader. BioRxiv. Posted February 29, 2024.
